JP2019533472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533472A5 JP2019533472A5 JP2019524363A JP2019524363A JP2019533472A5 JP 2019533472 A5 JP2019533472 A5 JP 2019533472A5 JP 2019524363 A JP2019524363 A JP 2019524363A JP 2019524363 A JP2019524363 A JP 2019524363A JP 2019533472 A5 JP2019533472 A5 JP 2019533472A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleotide
- sequence
- seq
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims description 49
- 108091034117 Oligonucleotide Proteins 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 48
- 230000000295 complement effect Effects 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091036055 CccDNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 101710142246 External core antigen Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940124765 capsid inhibitor Drugs 0.000 claims 1
- -1 capsid inhibitors Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 150000003611 tocopherol derivatives Chemical class 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420801P | 2016-11-11 | 2016-11-11 | |
| US62/420,801 | 2016-11-11 | ||
| US201762558770P | 2017-09-14 | 2017-09-14 | |
| US62/558,770 | 2017-09-14 | ||
| PCT/US2017/061348 WO2018089914A1 (en) | 2016-11-11 | 2017-11-13 | Oligonucleotide targeting strategy for hbv cccdna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533472A JP2019533472A (ja) | 2019-11-21 |
| JP2019533472A5 true JP2019533472A5 (OSRAM) | 2020-12-24 |
Family
ID=60452809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524363A Pending JP2019533472A (ja) | 2016-11-11 | 2017-11-13 | Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180179542A1 (OSRAM) |
| EP (1) | EP3538654A1 (OSRAM) |
| JP (1) | JP2019533472A (OSRAM) |
| KR (1) | KR20190076050A (OSRAM) |
| CN (1) | CN110234763A (OSRAM) |
| AU (1) | AU2017356221A1 (OSRAM) |
| CA (1) | CA3043637A1 (OSRAM) |
| IL (1) | IL266525A (OSRAM) |
| TW (1) | TW201831684A (OSRAM) |
| WO (1) | WO2018089914A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020004955A2 (pt) * | 2017-09-14 | 2020-10-06 | Janssen Biopharma, Inc. | derivados de galnac |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| CN114829599A (zh) * | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7653997B2 (ja) * | 2019-12-19 | 2025-03-31 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 |
| CN113493855B (zh) * | 2020-03-19 | 2023-12-26 | 首都医科大学附属北京佑安医院 | 一种基于RAA-CRISPR-cas13a检测HBV cccDNA的试剂盒 |
| EP4189089A1 (en) * | 2020-07-27 | 2023-06-07 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| CN116157522A (zh) * | 2020-08-21 | 2023-05-23 | 豪夫迈·罗氏有限公司 | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| CN118667808B (zh) * | 2023-08-22 | 2025-04-18 | 浙江柏拉阿图医药科技有限公司 | 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510319A (ja) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
| AR028149A1 (es) * | 1999-07-08 | 2003-04-30 | Innogenetics Nv | Deteccion de la resistencia a los farmacos contra la hepatitis b |
| MXPA02002577A (es) * | 1999-09-10 | 2003-10-14 | Geron Corp | N3'->p5'-tiofosforamidatos de oligonucleotido. |
| EP2316942B1 (en) * | 2004-12-22 | 2021-04-21 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| MX340408B (es) * | 2011-04-21 | 2016-07-07 | Ionis Pharmaceuticals Inc | Modulacion de la expresion del virus de hepatitis b (vhb). |
| BR112015027322A8 (pt) * | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | Compostos antissenso conjugados e sua utilização |
| JOP20200092A1 (ar) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| KR20170141257A (ko) * | 2015-05-06 | 2017-12-22 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스 (hbv) 감염의 치료를 위한 시약 및 이의 용도 |
-
2017
- 2017-11-13 WO PCT/US2017/061348 patent/WO2018089914A1/en not_active Ceased
- 2017-11-13 CN CN201780083173.6A patent/CN110234763A/zh not_active Withdrawn
- 2017-11-13 CA CA3043637A patent/CA3043637A1/en not_active Abandoned
- 2017-11-13 TW TW106139190A patent/TW201831684A/zh unknown
- 2017-11-13 KR KR1020197016640A patent/KR20190076050A/ko not_active Ceased
- 2017-11-13 AU AU2017356221A patent/AU2017356221A1/en not_active Abandoned
- 2017-11-13 US US15/810,857 patent/US20180179542A1/en not_active Abandoned
- 2017-11-13 JP JP2019524363A patent/JP2019533472A/ja active Pending
- 2017-11-13 EP EP17804414.5A patent/EP3538654A1/en not_active Withdrawn
-
2019
- 2019-05-08 IL IL266525A patent/IL266525A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533472A5 (OSRAM) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP2016502858A5 (OSRAM) | ||
| KR102774202B1 (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2015504650A5 (OSRAM) | ||
| JP2018520685A5 (OSRAM) | ||
| KR102025679B1 (ko) | Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2017538679A5 (OSRAM) | ||
| JP2019518037A (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| JP2018529732A5 (OSRAM) | ||
| JP2018507711A5 (OSRAM) | ||
| JP2015518710A5 (OSRAM) | ||
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| TW202006138A (zh) | Fubp1抑制劑用於治療b型肝炎病毒感染之用途 | |
| KR20230070330A (ko) | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 | |
| US20180179542A1 (en) | OLIGONUCLEOTIDE TARGETING STRATEGY FOR cccDNA | |
| JP2023550061A (ja) | オリゴヌクレオチド及びその抗ｂ型肝炎とｄ型肝炎ウイルスにおける応用 | |
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2018518167A5 (OSRAM) | ||
| CN115702006A (zh) | 缀合基团及其缀合物 | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| JPWO2023093896A5 (OSRAM) | ||
| JPWO2023004375A5 (OSRAM) |